Carlsmed, Inc. logo

Carlsmed, Inc.(CARL)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
Consider higher Upturn Star rating
BUY for 3 days
PROFIT SINCE LAST BUY
-7.96% ▼
LAST CLOSE
$17.12
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CARL

11/13/2026: CARL (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Carlsmed, Inc. is a commercial-stage medical technology company offering AI-enabled personalized solutions for spine surgery through its flagship aprevo platform. The company exhibits strong revenue growth driven by clinical adoption of its custom-built interbody fusion kits and surgical planning software. Its primary growth story rests on expanding market penetration within U.S. hospitals and ambulatory surgery centers, bolstered by favorable reimbursement updates. However, ongoing operating losses, a narrow product focus, and intense competition from larger medtech players present notable execution and concentration risks. The stock suits growth-oriented investors willing to accept high volatility, with close monitoring required on commercial scaling and reimbursement milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company delivers rapid top-line revenue expansion driven by the market adoption of its AI-enabled medical technology platform.
Momentum investorStrong fit while signal remains positiveThe stock frequently attracts trading interest following positive clinical updates, earnings beats, and upgraded annual guidance.
Value investorWeak fitCarlsmed is currently unprofitable and trades at early-stage growth multiples rather than traditional value metrics.
Dividend investorWeak fitThe company does not pay dividends, retaining all capital to fund commercialization and research.
Low-risk investorWeak fitHigh share price volatility and ongoing net operating losses expose investors to significant clinical and execution risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighAs an emerging commercial-stage medtech stock, share prices experience sharp fluctuations driven by market sentiment and news flow.
Valuation riskMedium / highValuations rely heavily on long-term growth assumptions rather than near-term earnings or cash generation.
Competition risk (AI and orthopedic incumbents)HighWell-capitalized medical device giants could develop competing technologies or leverage broader product bundles to challenge market share.
Business qualityMediumHigh gross margins and strong clinical differentiation are tempered by narrow product line concentration.
Dividend incomeLow / noneNo dividend is distributed to shareholders.
Execution riskHighContinued success depends heavily on expanding surgeon adoption, securing favorable hospital contracts, and navigating regulatory pathways.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 469.16M USD
Price to earnings Ratio -
1Y Target Price 22
Price to earnings Ratio -
1Y Target Price 22
Volume (30-day avg) 117.2K shares
Beta -
52 Weeks Range 8.50 - 19.15
Updated Date 11/15/2026
52 Weeks Range 8.50 - 19.15
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.13

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Health Information Services

BUY participation
100.0%
Active BUY / eligible
4 / 4
30-Day BUY Count Change
+2

Eligible universe: 4 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -41.02%
Avg. Invested days 17
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CARL receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
CARL has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, strong revenue growth (+85.9%) is partially offset by negative earnings growth (-22.2%), weak cash generation (FCF margin -58.6%), weak profitability (net margin -58.7%).

Financial Health Rating

★★★★★
CARL's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 86.4%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is CARL's strongest growth driver at +85.9% FY2025 versus FY2024 (strong, 5 stars). By comparison, while earnings growth (-22.2%, negative) and free-cash-flow growth (-15.5%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 42.3% and approximately 57.5% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 43.30% supports management-shareholder alignment.

Top 5 Institutional Investors

Jupiter Topco LLC 4.57%
Parkman Healthcare Partners LLC 2.18%
BlackRock Inc 1.94%
Pier Capital, LLC 1.89%
KCM Capital Inc 1.61%

Unit Economics (Per $1K Revenue)

★★★★★
CARL generates approximately $753 of gross profit, $-605 of operating income, and $-586 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 2-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
CARL has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Personalized Spine Surgery Systems (United States)Revenues generated from procedure kits incorporating AI-driven surgical software planning and custom-built interbody fusion implants sold to hospitals and ambulatory surgery centers.The company makes money by charging per-case fees for its customized surgical kits and software planning used in spine fusion operations.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 410.74M
Price to Sales(TTM) 6.54
Enterprise Value 410.74M
Price to Sales(TTM) 6.54
Enterprise Value to Revenue 5.72
Enterprise Value to EBITDA -
Shares Outstanding 27.40M
Shares Floating 15.75M
Shares Outstanding 27.40M
Shares Floating 15.75M
Percent Insiders 43.3
Percent Institutions 42.33

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.